复发性晚期直肠恶性黑色素瘤，在完全缓解后停用抗PD - 1抗体，并且对再挑战难以耐受

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2022-06-25 DOI:10.1002/cia2.12264

Shintaro Saito MD, Masahito Yasuda MD, PhD, Takeshi Araki MD, Azusa Ida MD, Yuko Kuriyama MD, PhD, Akihito Uehara MD, PhD, Chikako Kishi MD, PhD, Yukie Endo MD, PhD, Hiroomi Ogawa MD, PhD, Sei-ichiro Motegi MD, PhD

{"title":"复发性晚期直肠恶性黑色素瘤，在完全缓解后停用抗PD - 1抗体，并且对再挑战难以耐受","authors":"Shintaro Saito MD, Masahito Yasuda MD, PhD, Takeshi Araki MD, Azusa Ida MD, Yuko Kuriyama MD, PhD, Akihito Uehara MD, PhD, Chikako Kishi MD, PhD, Yukie Endo MD, PhD, Hiroomi Ogawa MD, PhD, Sei-ichiro Motegi MD, PhD","doi":"10.1002/cia2.12264","DOIUrl":null,"url":null,"abstract":"<p>We report a case of 70-year-old woman with rectal malignant melanoma that recurred in the pelvic lymph node one year after surgery. Nivolumab was initiated and she achieved complete response after one year, but she discontinued nivolumab at her instance. At a follow-up 21 months after the discontinuation of nivolumab, a pelvic lymph node metastasis recurrence and a lung metastasis discovered. Nivolumab rechallenge was initiated, but it was not successful.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12264","citationCount":"1","resultStr":"{\"title\":\"Recurrent advanced rectal malignant melanoma that discontinued anti-PD-1 antibody after complete response and was refractory to rechallenge\",\"authors\":\"Shintaro Saito MD, Masahito Yasuda MD, PhD, Takeshi Araki MD, Azusa Ida MD, Yuko Kuriyama MD, PhD, Akihito Uehara MD, PhD, Chikako Kishi MD, PhD, Yukie Endo MD, PhD, Hiroomi Ogawa MD, PhD, Sei-ichiro Motegi MD, PhD\",\"doi\":\"10.1002/cia2.12264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We report a case of 70-year-old woman with rectal malignant melanoma that recurred in the pelvic lymph node one year after surgery. Nivolumab was initiated and she achieved complete response after one year, but she discontinued nivolumab at her instance. At a follow-up 21 months after the discontinuation of nivolumab, a pelvic lymph node metastasis recurrence and a lung metastasis discovered. Nivolumab rechallenge was initiated, but it was not successful.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12264\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

摘要

粘膜黑色素瘤(Mucosal melanoma, MCM)是一种临床上罕见的黑色素瘤亚型，在美国占所有亚型的比例不到1%，而在亚洲，MCM是第二常见的临床亚型，占所有黑色素瘤亚型的22.6%，2直肠黑色素瘤(直肠黑色素瘤，RM)占所有MCM的19%，是仅次于外阴黑色素瘤的第二常见亚型抗pd1抗体对MCM的疗效低于皮肤黑色素瘤。在不可切除的胃肠道黑色素瘤中，抗pd1抗体的完全缓解率(CR)和部分缓解率分别只有7%和19%我们在此报告第一例在CR后停止抗pd1抗体再挑战的RM病例。一名70岁的女性，抗着丝点抗体阳性系统性硬化症病史4年，接受贝拉前列素钠治疗，出现粪便隐血。她被诊断为RM，并接受了腹腔镜腹部会阴切除术(图1A)。病理结果显示非典型黑素细胞增生并浸润到粘膜下层(图1B)。一个

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$Recurrent advanced rectal malignant melanoma that discontinued anti-PD-1 antibody after complete response and was refractory to rechallenge$

查看原文本刊更多论文

Recurrent advanced rectal malignant melanoma that discontinued anti-PD-1 antibody after complete response and was refractory to rechallenge

We report a case of 70-year-old woman with rectal malignant melanoma that recurred in the pelvic lymph node one year after surgery. Nivolumab was initiated and she achieved complete response after one year, but she discontinued nivolumab at her instance. At a follow-up 21 months after the discontinuation of nivolumab, a pelvic lymph node metastasis recurrence and a lung metastasis discovered. Nivolumab rechallenge was initiated, but it was not successful.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks